The impact of different definitions and reference groups on the prevalence of cognitive impairment: A study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy

Psycho-Oncology

Volumn 19, Issue 4, 2010, Pages 415-422

  Schilder, Christina M ^a   Seynaeve, Caroline ^b   Linn, Sabine C ^a   Boogerd, Willem ^a,c   Gundy, Chad M ^a   Beex, Louk V ^d   Van Dam, Frits S ^a   Schagen, Sanne B ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Slotervaart Medical Center   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant systemic therapy; Cancer; Cognitive impairment; Neuropsychological tests; Oncology

Indexed keywords

ADJUVANT SYSTEMIC THERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; COGNITIVE DEFECT; CONTROLLED STUDY; CRITERION VARIABLE; DISEASE CLASSIFICATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NEUROPSYCHOLOGICAL TEST; POSTMENOPAUSE; PREVALENCE; SYSTEMIC THERAPY;

ADJUVANTS, PHARMACEUTIC; AGE FACTORS; AGED; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; REFERENCE VALUES;

EID: 77950883019     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1595     Document Type: Article

References (35)

1. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22:2233-2239.
2. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004;101:466-475.
3. Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 2005;14:70-78. (Pubitemid 40124675)
4. Fan HG, Houede-Tchen N, Yi QL et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005;23:8025-8032. (Pubitemid 46657404)
5. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, Van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006;98:1742-1745. (Pubitemid 44942713)
6. Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006;54:925-931. (Pubitemid 43847029)
7. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828-834.
8. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006;15:422-430. (Pubitemid 43826855)
9. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109:1905-1913. (Pubitemid 46668557)
10. Ahles TA, Saykin AJ, McDonald BC et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008;110:143-152. (Pubitemid 351793851)
11. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008;17:122-130. (Pubitemid 351279862)
12. Castellon SA, Silverman DH, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005;92:199-206.
13. Newman S, Stygall J, Hirani S, Shaefi S, Maze M. Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology 2007;106: 572-590. (Pubitemid 46662224)
14. Vardy JL, Booth C, Pond GR et al. Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. J Clin Oncol 2007;25:abstr. 9070.
15. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7:192-201. (Pubitemid 46310497)
16. Shilling V, Jenkins V, Trapala IS. The (mis)classi.cation of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006;95:125-129.
17. Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc 2007;55:1534-1540.
18. Rasmussen LS, Larsen K, Houx P, Skovgaard LT, Hanning CD, Moller JT. The assessment of postoperative cognitive function. Acta Anaesthesiol Scand 2001;45:275-289.
19. Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
20. Schilder CM, Eggens PC, Seynaeve C et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48:76-85.
21. Van der Meulen EF, Schmand B, van Campen JP et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004;75:700-705. (Pubitemid 38526679)
22. van den BurgW, Saan RJ, Deelman BG. 15-woordentest. Provisional Manual. University Hospital, Department of Neuropsychology, Groningen, 1985.
23. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73: 126-133.
24. Wechsler D. Wechsler Memory Scale: Revised. Psychological Corporation: New York, 1987.
25. Wechsler D. WAIS-III Nederlandstalige Bewerking. Technische Handleiding. Swets & Zeitlinger: Lisse, 2000.
26. Hammes J. De Stroop kleur-woord test. Handleiding (2nd edn). Swets & Zeitlinger: Lisse, 1978.
27. Reitan R. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
28. Alpherts W, Aldenkamp AP. FePsy: The Iron Psyche. Instituut voor Epilepsiebestrijding, Heemstede, 1994.
29. Schmand B, Groenink SC, van den Dungen M. Letter fluency: psychometric properties and Dutch normative data (Letterfluency: psychometrische eigenschappen en Nederlandse normen). Tijdschr Gerontol Geriatr 2008;39:64-76.
30. Van der Elst W, van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the animal, profession and letter M naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006;12:80-89.
31. Comijs HC, Kriegsman DWM, Dik MG et al. Somatic chronic diseases and 6-year change in cognitive functioning among older persons. Archives of Gerontology and Geriatics 2009;48:191-196.
32. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003;24:133-151.
33. Schmand B, Lindeboom J, van Harskamp F. De Nederlandse Leestest Voor Volwassenen. Swets & Zeitlinger: Lisse, 1992.
34. Lezak M. Neuropsychological Assessment. Oxford University Press: New York, 2004.
35. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-629.